1. Home
  2. LDI vs TSHA Comparison

LDI vs TSHA Comparison

Compare LDI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$0.69

Market Cap

542.4M

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.91

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
TSHA
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
542.4M
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
LDI
TSHA
Price
$0.69
$4.91
Analyst Decision
Sell
Strong Buy
Analyst Count
3
8
Target Price
$3.00
$11.63
AVG Volume (30 Days)
6.3M
2.2M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
N/A
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
$17.58
N/A
Revenue Next Year
$13.99
$1,152.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.28
52 Week Low
$0.68
$3.04
52 Week High
$3.80
$7.30

Technical Indicators

Market Signals
Indicator
LDI
TSHA
Relative Strength Index (RSI) 37.84 38.74
Support Level $0.68 $4.37
Resistance Level $1.32 $6.01
Average True Range (ATR) 0.07 0.21
MACD -0.01 -0.00
Stochastic Oscillator 17.35 31.37

Price Performance

Historical Comparison
LDI
TSHA

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: